Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX)
Phase IIIb Study Minimizing Adverse Haemmhorragic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX)
Sponsor: Eustrategy
Listed as NCT01433627, this PHASE3 trial focuses on Acute Coronary Syndromes and NSTEMI and remains ongoing. Sponsored by Eustrategy, it has been updated 6 times since 2011, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
First recorded
Oct 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eustrategy
- Italian Society of Invasive Cardiology
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arezzo, Italy , Ascoli Piceno, Italy , Bari, Italy , Bologna, Italy , Brescia, Italy , Carbonia, Italy , Catania, Italy , Catanzaro, Italy , Chieti, Italy , Como, Italy and 43 more locations